SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : T/FIF, a New Plateau
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (1484)10/24/2002 2:22:30 PM
From: scaram(o)uche  Read Replies (2) of 2243
 
>> If so, maybe BTRN would be a buy if/when MEDI goes that way, or if they return the rights to BTRN and BTRN goes that way <<

I never addressed your major point..... sure, but that's a long way off.

I think that BTRN should determine what serological responses to vitaxin look like in MEDI's hands.

Let's not forget that MEDI humanized the antibody. And why is this shocking (not!) immunogenicity just now -- after such an extended period of human testing -- coming to light?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News